Replimune Group, Inc. (NASDAQ:REPL) Receives Average Recommendation of “Buy” from Brokerages

Replimune Group, Inc. (NASDAQ:REPL) has earned a consensus recommendation of “Buy” from the six research firms that are presently covering the firm, Marketbeat Ratings reports. Five analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the company. The average 1-year target price among analysts that have issued ratings on the stock in the last year is $16.80.

Several analysts have weighed in on the company. Roth Capital raised Replimune Group to a “strong-buy” rating in a report on Tuesday, August 27th. JPMorgan Chase & Co. increased their price target on shares of Replimune Group from $14.00 to $17.00 and gave the company an “overweight” rating in a research report on Tuesday, September 24th. HC Wainwright reaffirmed a “buy” rating and issued a $17.00 target price on shares of Replimune Group in a research note on Monday, September 16th. Finally, Roth Mkm initiated coverage on Replimune Group in a research report on Tuesday, August 27th. They set a “buy” rating and a $17.00 price target for the company.

Replimune Group Trading Up 5.5 %

Shares of Replimune Group stock opened at $11.97 on Friday. The company has a 50-day moving average of $10.86 and a two-hundred day moving average of $8.92. Replimune Group has a 12-month low of $4.92 and a 12-month high of $15.18. The company has a current ratio of 13.46, a quick ratio of 13.46 and a debt-to-equity ratio of 0.16. The stock has a market cap of $817.79 million, a PE ratio of -3.66 and a beta of 1.21.

Replimune Group (NASDAQ:REPL) last released its quarterly earnings results on Thursday, August 8th. The company reported ($0.78) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.88) by $0.10. On average, research analysts anticipate that Replimune Group will post -3.05 EPS for the current fiscal year.

Insiders Place Their Bets

In other Replimune Group news, CFO Emily Luisa Hill sold 8,938 shares of the business’s stock in a transaction on Friday, August 16th. The stock was sold at an average price of $10.18, for a total value of $90,988.84. Following the completion of the transaction, the chief financial officer now directly owns 101,057 shares in the company, valued at approximately $1,028,760.26. The trade was a 0.00 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which is accessible through this link. 8.80% of the stock is owned by corporate insiders.

Institutional Trading of Replimune Group

Several hedge funds and other institutional investors have recently added to or reduced their stakes in REPL. Millennium Management LLC lifted its holdings in shares of Replimune Group by 575.1% during the 2nd quarter. Millennium Management LLC now owns 3,118,035 shares of the company’s stock worth $28,062,000 after acquiring an additional 2,656,173 shares during the period. Goldman Sachs Group Inc. boosted its holdings in shares of Replimune Group by 300.3% in the 4th quarter. Goldman Sachs Group Inc. now owns 2,238,883 shares of the company’s stock valued at $18,874,000 after purchasing an additional 1,679,553 shares during the last quarter. Price T Rowe Associates Inc. MD grew its stake in shares of Replimune Group by 12.0% during the 1st quarter. Price T Rowe Associates Inc. MD now owns 6,548,930 shares of the company’s stock valued at $53,505,000 after buying an additional 699,679 shares during the period. Jacobs Levy Equity Management Inc. purchased a new stake in shares of Replimune Group during the 1st quarter valued at $1,088,000. Finally, Acadian Asset Management LLC acquired a new stake in shares of Replimune Group during the 1st quarter worth $927,000. Hedge funds and other institutional investors own 92.53% of the company’s stock.

About Replimune Group

Replimune Group, Inc, a clinical-stage biotechnology company, focuses on the development of oncolytic immunotherapies to treat cancer. The company's proprietary tumor-directed oncolytic immunotherapy product candidates are designed and intended to activate the immune system against cancer. Its lead product candidate is RP1, a selectively replicating version of HSV-1 that expresses GALV-GP R(-) and human GM-CSF, which is in Phase I/II clinical trials for a range of solid tumors; and that has completed Phase II clinical trials for treating cutaneous squamous cell carcinoma.